Zambia to India Pharmaceutical Import

The pharmaceutical trade corridor between Zambia and India has experienced modest activity from 2022 to 2026. Over this period, India imported a total of $190 USD worth of finished pharmaceutical formulations from Zambia, comprising two shipments. The primary products imported were Artemether and Tenofovir, indicating a focus on antimalarial and antiretroviral treatments. The average shipment value stood at $95 USD, reflecting a niche yet consistent trade relationship. This limited volume suggests that while the corridor exists, it remains underdeveloped compared to other international pharmaceutical trade routes.

Zambia's contribution to India's pharmaceutical imports is minimal, accounting for a fraction of the total import value. The imports are concentrated in specific therapeutic areas, notably antimalarial and antiretroviral drugs. This specialization indicates that Zambia's pharmaceutical exports to India are tailored to meet particular medical needs, rather than offering a broad spectrum of products.

Between 2024 and 2026, there have been no significant policy changes by the Central Drugs Standard Control Organisation (CDSCO) specifically affecting the import of pharmaceutical products from Zambia. Similarly, no new trade agreements or regulatory harmonization efforts have been reported that would impact this bilateral trade corridor. The lack of such developments suggests a period of regulatory stability, albeit with limited initiatives to enhance trade relations in the pharmaceutical sector between the two nations.

IMPORT_REGULATORY

For Zambian pharmaceutical companies aiming to export finished formulations to India, obtaining approval from the CDSCO is mandatory. The process involves several key steps:

1. Application Submission: Companies must submit an Integrated Registration Form (IRF) through the CDSCO's SUGAM portal, providing comprehensive details about the product and manufacturing processes.

2. Documentary Requirements: Essential documents include a Power of Attorney, Site Master File, Manufacturing Licenses, Free Sale Certificate, and a list of products intended for export.

3. Verification and Approval: Upon submission, the application undergoes verification by CDSCO officials. This may involve site inspections to ensure compliance with Indian regulatory standards.

The entire process can take several months, depending on the completeness of the application and the efficiency of the verification procedures.

India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards as outlined by the World Health Organization (WHO). Zambian manufacturers must ensure their facilities comply with these standards to qualify for export to India. The CDSCO conducts inspections to verify adherence to GMP guidelines, assessing aspects such as facility cleanliness, equipment calibration, and personnel training. Non-compliance can result in delays or rejections of import applications.

To import pharmaceutical products into India, Zambian companies must secure an Import License (Form 10) from the CDSCO. This license authorizes the importation of specific drugs and ensures they meet Indian quality standards. Additional required documents include a Registration Certificate, No Objection Certificate (NOC), Test License, and compliance with customs procedures. These documents collectively facilitate the legal entry and distribution of pharmaceutical products within India.

IMPORT_TRENDS

India's pharmaceutical imports from Zambia are predominantly focused on antimalarial and antiretroviral drugs, specifically Artemether and Tenofovir. Artemether, an antimalarial agent, constitutes 92.2% of the import value, while Tenofovir, an antiretroviral medication, accounts for 7.8%. This concentration indicates that Zambia's pharmaceutical exports to India are specialized, catering to specific therapeutic needs rather than a broad range of products.

The imports from Zambia to India are centered on established pharmaceutical formulations, such as Artemether and Tenofovir. There is no evidence of the importation of innovator drugs, novel formulations, or advanced therapies from Zambia to India. This suggests that Zambia's pharmaceutical exports to India are limited to well-established treatments without significant innovation or specialization.

India's importation of pharmaceutical products from Zambia is likely driven by specific therapeutic needs, particularly in the areas of malaria and HIV treatment. The demand for Artemether and Tenofovir may be influenced by factors such as patent protection, quality requirements, and the need to address disease burdens that are prevalent in certain regions. However, the limited volume of trade suggests that these factors are not leading to a substantial increase in imports from Zambia.

IMPORT_POLICY

India's import tariff structure for pharmaceutical formulations includes the Most Favored Nation (MFN) tariff rates, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. The specific rates can vary based on the product classification and prevailing trade policies. These tariffs are designed to regulate the import of pharmaceutical products, ensuring that imported drugs meet Indian standards and are priced competitively.

As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Zambia concerning pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations, but there are no bilateral agreements that offer preferential treatment for pharmaceutical products.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents by disallowing patents on new forms of known substances unless they result in enhanced efficacy. This provision can impact the importation of certain pharmaceutical products. Additionally, the National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, including imported ones, to ensure affordability. These policies can influence the dynamics of pharmaceutical imports, including those from Zambia.

IMPORT_LOGISTICS

Pharmaceutical shipments from Zambia to India are likely transported via sea routes, with transit times varying based on the specific ports of departure and arrival. The reliability of these routes is generally high, but factors such as weather conditions and port congestion can affect delivery schedules. Air freight options are also available but may be less commonly used due to higher costs.

Zambia's primary export ports include the Port of Dar es Salaam in Tanzania and the Port of Durban in South Africa, both of which are accessible via road and rail from Zambia. In India, major import ports handling pharmaceutical shipments include the Jawaharlal Nehru Port in Mumbai and the Chennai Port. These ports are equipped to handle pharmaceutical imports, ensuring compliance with regulatory standards and efficient processing of shipments.

Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes verification of import documentation and compliance with CDSCO regulations. The CDSCO may conduct testing to ensure product quality and safety. Cold chain management is critical for certain pharmaceutical products, and importers must ensure that their logistics partners adhere to Good Distribution Practice (GDP) guidelines to maintain product integrity throughout the supply chain.

IMPORT_OPPORTUNITY

Despite being a major pharmaceutical manufacturer, India imports specific drugs from Zambia, such as Artemether and Tenofovir, likely due to factors like patent protection, quality requirements, and the need to address disease burdens that are prevalent in certain regions. However, the limited volume of trade suggests that these imports are not a significant component of India's overall pharmaceutical needs.

Zambian pharmaceutical companies exporting to India are likely to be small to medium-sized enterprises focusing on specific therapeutic areas. Their strategies may include establishing partnerships with Indian distributors, ensuring compliance with CDSCO regulations, and maintaining high-quality manufacturing standards to meet Indian market requirements.

India's "Atmanirbhar Bharat" initiative and the Production-Linked Incentive (PLI) scheme aim to boost domestic pharmaceutical manufacturing. While these policies may reduce India's reliance on imports, the specialized nature of certain pharmaceutical products from Zambia could continue to meet specific needs not fully addressed by domestic production. However, the limited volume of trade suggests that imports from Zambia may not experience significant growth in the near future.

IMPORT_COMPETITIVE

India imports pharmaceutical products from various countries, including the USA, EU, China, Switzerland, and Japan. Zambia's share in this import landscape is minimal, with other countries supplying a broader range of products and larger volumes. This competitive environment presents challenges for Zambia to expand its pharmaceutical exports to India.